Lenz G, Dreyling M, Unterhalt M, Hiddemann W
Medizinische Klinik III, Klinikum der Ludwig Maximilians-Universität, München.
Dtsch Med Wochenschr. 2004 Nov 5;129(45):2429-33. doi: 10.1055/s-2004-835284.
Advanced stage mantle cell lymphoma (MCL) with a median survival of only three years and virtually no long-term survivors represents the lymphoma subtype with the poorest prognosis and remains incurable with conventional chemotherapy. Recently two randomized trials of the German Low Grade Lymphoma Study Group (GLSG) demonstrated the superiority of a combined immunochemotherapy with the anti-CD20 antibody rituximab in first-line therapy (R-CHOP) as well as in relapsed disease (R-FCM). In addition, in a trial of the European MCL Network, intensified-consolidation with high-dose radiochemotherapy followed by autologous stem cell transplantation significantly improved the progression-free survival in patients up to 65 years of age. However, the vast majority of patients with MCL will eventually relapse. Thus, new strategies such as allogenic transplantation after dose-reduced conditioning or novel molecular targeting agents (e. g. proteasome inhibitors or radiolabeled antibodies) are urgently warranted to further improve the long-term outcome of MCL.
晚期套细胞淋巴瘤（MCL）的中位生存期仅为三年，几乎没有长期存活者，是预后最差的淋巴瘤亚型，传统化疗无法治愈。最近，德国低度淋巴瘤研究组（GLSG）的两项随机试验表明，在一线治疗（R-CHOP）以及复发疾病（R-FCM）中，联合使用抗CD20抗体利妥昔单抗的免疫化疗具有优势。此外，在欧洲MCL网络的一项试验中，采用大剂量放化疗强化巩固治疗，随后进行自体干细胞移植，显著改善了65岁以下患者的无进展生存期。然而，绝大多数MCL患者最终会复发。因此，迫切需要新的策略，如减剂量预处理后的异基因移植或新型分子靶向药物（如蛋白酶体抑制剂或放射性标记抗体），以进一步改善MCL的长期治疗效果。
